Latest Discovery Provides Hope For Early Detection Of Serious COVID-19

Brisbane: Australian researchers have developed a way of testing whether or not COVID-19 patients’ immune systems are gearing up to fight the virus that causes the deadly disease. The researchers from QIMR Berghofer Medical Research Institute hope the discovery could be used to identify early on which patients’ immune systems are not responding appropriately, and who might be at higher risk of becoming seriously unwell. The prototype test detects high levels of two key chemical signals that are produced by T cells when they recognise SARS-CoV-2-infected cells and start to fight the infection. SARS-CoV-2 is a virus that causes COVID-19.

Also Read: Antibodies In Mucous Membrane May Dominate Early COVID-19 Immune Response: Study

T cells are the immune cells that recognise and destroy cells infected with SARS-CoV-2. Study leader and the head of QIMR Berghofer’s Translational and Human Immunology Group, Associate Professor Corey Smith, said the researchers examined blood donated by 44 Queenslanders who had recovered from COVID-19 to find out which combination of viral peptides could be used to stimulate T cells in the laboratory and allow researchers to measure their response to SARS-CoV-2.

T cells produce a range of signalling molecules when they fight viruses, Associate Professor Corey Smith said.

Also Read: COVID-19: ‘Don’t Hug’ Is World Health Organisation’s Advice For The Holidays

These signalling molecules are basically indicators of whether T cells are responding to the SARS-CoV-2 virus and are mobilising the immune army to launch an attack. If we can find a way to detect whether or not they are present, then we can find out whether or not a patient’s immune system is responding as it should, Corey Smith added.

We isolated the T cells from the donated blood, exposed them to viral peptides, and measured the production of a number of different signalling molecules. We then compared the levels produced by T cells from the recovered COVID-19 patients with levels released by T cells from 20 healthy donors who had never been infected with SARS-CoV-2, said Corey Smith.

Also Read: World Health Organisation Says Almost All COVID-19 Cases Develop Immune Response

The researchers found that T cells from people who had recovered from COVID-19 produced larger amounts of the signalling molecules interferon-gamma and interleukin-2, which are involved in killing virus-infected cells and encouraging other T cells to come to the infected area.

Details of the study have been published on Monday (December 7) in the journal Clinical and Translational Immunology.

Also Read: New Smartphone-Based COVID-19 Test Gives Results In Less Than 30 Minutes

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.